James T Rosenbaum is an expert in Ophthalmology at Legacy Devers Eye Institute (United States). As of October 2026, ScienceLeadR ranks James T Rosenbaum in the top 1% of experts worldwide for Uveitis, Uveal Diseases and Arthritis. James T Rosenbaum has authored 625 publications, the most recent in 2026, and is an investigator in 10 clinical trials. SLR score: 2,343 (community average: 125). How the SLR is computed.

LeadR Profile

James T Rosenbaum Legacy Devers Eye Institute United States
2 343 ScienceLeadR Reputation 2343
Network Map

Ophthalmology

Subspecialties: Immunology - Internal Medicine - Rheumatology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1987 - 2026

Source: PubMed

Legacy Health

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 625

Citations

Citations: 33 326 1st author: 116 Last author: 230 Unique author: 46


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Towards Understanding Retinal Vasculitis: Definitions from an Expert Panel.
PMID 42578656 — vasculitis, retinal vasculitis, arthritis, rheumatic diseases, retinaldehyde
Arthritis Rheumatol20260
Last Man Running.
PMID 42573353 — running
N Engl J Med Top journal20260
Standardization of Retinal Vasculitis Terminology With Consensus Definitions From a Delphi Panel.
PMID 42560698 — vasculitis, retinal vasculitis, communication, research, eye diseases, retinaldehyde
JAMA Ophthalmol20261
Risk of Cataract and Ocular Hypertension in Chronic Anterior Uveitis Patients on Stable-Dosing of Topical Corticosteroids.
PMID 42531486 — eye, hypertension, prednisolone, uveitis, anterior, adrenal cortex hormones, ocular hypertension, cataract, uveitis, intraocular pressure
Ocul Immunol Inflamm20260
Soquelitinib inhibition of IL-2-inducible T cell kinase ameliorates lung damage in murine models of systemic sclerosis.
PMID 41437110 — cells, sclerosis, lung, arthritis, interleukin-2, t-lymphocytes, scleroderma, systemic
Arthritis Res Ther20250

Clinical Studies 10

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2 Study Director: 3

By phase:

Phase 2 3
N/A 2
Phase 1/Phase 2 2
Phase 1 1
Phase 3 1
Phase 4 1

By status:

Completed 8
Terminated 2

By type:

Interventional 9
Observational 1

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 1
multicentric5to9 0
multicentricup10 3

Main Topics

Cohort/Consortium Investigators 14

LeadR Networks

Main global connection map